Submissions for variant NM_000492.4(CFTR):c.50del (p.Phe17fs)

Minimum review status:		Collection method:
Minimum conflict level: Report conflict between different conditions
		ClinVar version:

Total submissions: 6

Download table as spreadsheet

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
CFTR2	RCV000047175	SCV000245951	pathogenic	Cystic fibrosis	2017-03-17	reviewed by expert panel	research
CeGaT Center for Human Genetics Tuebingen	RCV001093483	SCV001250497	pathogenic	not provided	2019-05-01	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000047175	SCV001587689	pathogenic	Cystic fibrosis	2022-08-16	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Phe17Serfs*8) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 7515303, 23974870). ClinVar contains an entry for this variant (Variation ID: 53984). For these reasons, this variant has been classified as Pathogenic.
Institute of Human Genetics, University of Leipzig Medical Center	RCV000047175	SCV002574002	pathogenic	Cystic fibrosis	2022-09-05	criteria provided, single submitter	curation	This variant was identified in 2 unrelated patients with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PVS1, PM2_SUP, PM3_STR
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000047175	SCV004099764	pathogenic	Cystic fibrosis	2023-09-12	criteria provided, single submitter	clinical testing	Variant summary: CFTR c.50delT (p.Phe17SerfsX8) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 250742 control chromosomes (gnomAD). c.50delT has been reported in the literature in individuals affected with Cystic Fibrosis (e.g. Shackelton_1994, Hirtz_2004, Tosco_2016). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 15480987, 7515303, 27035618). Five ClinVar submitters have assessed the variant since 2014, and all five classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Natera, Inc.	RCV001831794	SCV002080059	pathogenic	CFTR-related disorder	2017-03-17	no assertion criteria provided	clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.